{"id":"NCT01471444","sponsor":"M.D. Anderson Cancer Center","briefTitle":"Fludarabine-IV Busulfan Â± Clofarabine and Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)","officialTitle":"A Randomized Study of Once Daily Fludarabine-Clofarabine Versus Fludarabine Alone Combined With Intervenous Busulfan Followed by Allogeneic Hemopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-11-02","primaryCompletion":"2020-12-14","completion":"2020-12-14","firstPosted":"2011-11-15","resultsPosted":"2021-12-16","lastUpdate":"2021-12-16"},"enrollment":256,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Disorder Related to Bone Marrow Transplantation","Leukemia","Transplantation Infection"],"interventions":[{"type":"DRUG","name":"Fludarabine","otherNames":["Fludarabine Phosphate","Fludara"]},{"type":"DRUG","name":"Clofarabine","otherNames":["Clofarex","Clolar"]},{"type":"DRUG","name":"Busulfan","otherNames":["Busulfex","Myleran"]},{"type":"DRUG","name":"Thymoglobulin","otherNames":["ATG","Antithymocyte Globulin"]},{"type":"PROCEDURE","name":"Stem Cell Infusion","otherNames":["Bone marrow transplant"]},{"type":"DRUG","name":"Tacrolimus","otherNames":["Prograf"]},{"type":"DRUG","name":"Methotrexate","otherNames":[]}],"arms":[{"label":"Flu + Bu","type":"EXPERIMENTAL"},{"label":"Flu +Clo + Bu","type":"EXPERIMENTAL"}],"summary":"The goal of this clinical research study is to learn if combining busulfan with clofarabine and fludarabine can help control the disease better than the previous standard method (using busulfan and fludarabine alone) in patients with AML or MDS. The safety of this combination therapy will also be studied.","primaryOutcome":{"measure":"Progression-Free Survival (PFS)","timeFrame":"From day of transplant to disease of progression or death of any cause, whichever came first, assessed up to 5 years","effectByArm":[{"arm":"Arm A (Flu+Bu)","deltaMin":69,"sd":null},{"arm":"Arm B (Flu+Clo+Bu)","deltaMin":61,"sd":null}],"pValues":[]},"eligibility":{"minAge":"3 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":25,"n":130},"commonTop":["Nausea","Mucositis","Elevated transminitis","Infections","Skin GvHD"]}}